VBL Therapeutics announced the appointment of Matthew Trudeau to the newly created position of Chief Commercial Officer (CCO). Mr. Trudeau will be responsible for all commercialization activity for ofranergene obadenovec (ofra-vec, or VB-111). His appointment further advances VBL's strategic plan to become a commercial organization and establish operations in the United States.

Matthew Trudeau brings over 25 years of U.S. and international experience commercializing complex biological products. He has experience leading all aspects of commercial practice at both small and large biotech companies. From 2016 to 2021, he held positions of increasing responsibility at bluebird bio, culminating in his appointment as Head of the U.S. business team.

In this role, he led the design and implementation of bluebird's commercial operating model and was accountable for all aspects of U.S. commercialization for an innovative gene therapy portfolio.